CompletedPhase 1NCT00002890

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Studying Acute myelomonocytic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Joseph G. Jurcic, MD
Memorial Sloan Kettering Cancer Center
Intervention
lintuzumab(biological)
Enrollment
24 enrolled
Eligibility
16 years · All sexes
Timeline
19962001

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00002890 on ClinicalTrials.gov

Other trials for Acute myelomonocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute myelomonocytic leukemia

← Back to all trials